← All trials
NCT00031681
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2001
- Primary completion
- Jan 1, 2011
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 41
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- University of VirginiaOverall official - principal investigator
- Washington University in St. LouisCollaborator
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Appendix
- Bile Duct Neoplasms
- Breast Neoplasms
- Basal Cell Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Uterine Cervical Neoplasms
- Colonic Neoplasms
- Carcinoma, Adenoid Cystic
- Esophageal Neoplasms
- Gallbladder Neoplasms
- Graft vs Host Disease
- Granuloma
- Intestinal Neoplasms
- Liver Neoplasms
- Lymphoma
- Nasopharyngeal Neoplasms
- Neoplasm Metastasis
- Neoplasms
- Neuroblastoma
- Oropharyngeal Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Rectal Neoplasms
- Salivary Gland Neoplasms
- Stomach Neoplasms
- Colorectal Neoplasms
- Endometrial Neoplasms
- Carcinoma, Mucoepidermoid
- Carcinoma, Verrucous
- Papilloma, Inverted
- Gastrointestinal Stromal Tumors
- Small Cell Lung Carcinoma
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.